BioCorRx (BICX) Short term Debt (2021 - 2023)

BioCorRx has reported Short term Debt for 4 years, with the latest figure at $3.1 million in Q2 2022.

• Quarterly Short term Debt rose 18.19% year-over-year to $3.1 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $3.1 million (up 18.19% YoY) and the FY2021 annual result came in at $31580.0, down 98.68% from the prior year.
• Short term Debt improved to $3.1 million in Q2 2022 per BICX's latest filing, from $3.0 million in the prior quarter.
• Over five years, Short term Debt peaked at $3.1 million in Q2 2022 and troughed at $31580.0 in Q4 2021.
• A 4-year average of $2.3 million and a median of $2.5 million in 2021 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2020 and 2021: Short term Debt advanced 25.17% in 2020, then sank 98.68% in 2021.
• Over 4 years, Short term Debt stood at $1.9 million in 2019, then advanced by 25.17% to $2.4 million in 2020, then tumbled by 98.68% to $31580.0 in 2021, then surged by 9721.92% to $3.1 million in 2022.
• According to Business Quant data, Short term Debt over the past three periods registered $3.1 million, $3.0 million, and $31580.0 for Q2 2022, Q1 2022, and Q4 2021 respectively.